©Author(s) (or their employer(s)) 2026.
World J Clin Pediatr. Mar 9, 2026; 15(1): 115246
Published online Mar 9, 2026. doi: 10.5409/wjcp.v15.i1.115246
Published online Mar 9, 2026. doi: 10.5409/wjcp.v15.i1.115246
Table 1 Socio-demographic, clinical characteristics and scores of children with generalized anxiety disorder and control, n (%)/median (interquartile range)
| Parameters | GAD group (n = 25) | Control group (n = 30) | P value |
| Gender | 0.128 | ||
| Female | 18 (72) | 15 (50) | |
| Male | 7 (28) | 15 (50) | |
| Family history of chronic illnesses | 13 (52.0) | 21 (65.6) | 0.298 |
| Family history of psychiatric disorders | 14 (56) | 8 (26.7) | 0.019 |
| Smoking (yes) | 1 (3.8) | 0 (0) | 0.464 |
| COVID-19 history (yes) | 12 (46.2) | 12 (40.0) | 0.64 |
| Parents together (yes) | 23 (88.5) | 26 (86.7) | 0.839 |
| Age (years) | 160 (135-185) | 154 (128-177) | 0.271 |
| BMI percentile | 45 (22-80) | 61 (19.1-82) | 0.622 |
| Time since symptom onset (months) | 11 (6-25) | ||
| RCADS-CV scores | |||
| SAD | 60 (53-70) | 44.5 (41-51) | < 0.001 |
| GAD | 59 (54-68) | 42 (39-47) | < 0.001 |
| PD | 68 (52-80) | 43.5 (39-52) | < 0.001 |
| SP | 54 (42-72) | 39 (33-44) | < 0.001 |
| OCD | 60 (52-69) | 46.5 (38-51.3) | < 0.001 |
| MDD | 61 (44-75) | 42.5 (38-52) | < 0.001 |
| Total | 65 (51-75) | 41 (37-47) | < 0.001 |
Table 2 Comparison of biochemical measure levels between the generalized anxiety disorder and control groups, median (interquartile range)
| GAD group (n = 25) | Control group (n = 30) | P value1 | |
| CRP (mg/L) | 1.7 (1.2-2.94) | 1.3 (1.2-1.7) | 0.034 |
| TNF-α (pg/mL) | 7.9 (6.4-11.0) | 9.3 (7.7-11.0) | 0.466 |
| TWEAK (mg/L) | 1111 (893-1889) | 1236 (1009-1380) | 0.980 |
| IL-6 (pg/mL) | 2.8 (0.75-3.99) | 2.8 (0.8-4.0) | 0.615 |
| IFN-γ (ng/mL) | 59.4 (38.4-95.4) | 61.6 (54-84) | 0.628 |
| Zinc (μg/dL) | 94 (82-104) | 100 (93-112) | 0.073 |
| Neopterin (nmol/L) | 3.66 (1.84-4.74) | 2.9 (2.2-3.9) | 0.674 |
- Citation: Ünal K, Taş Torun Y, Erol ME, Kurt ZK, Özbaş C. Could high serum C-reactive protein levels serve as a biomarker for children and adolescents diagnosed with generalized anxiety disorder? World J Clin Pediatr 2026; 15(1): 115246
- URL: https://www.wjgnet.com/2219-2808/full/v15/i1/115246.htm
- DOI: https://dx.doi.org/10.5409/wjcp.v15.i1.115246
